Bench C J, Lammertsma A A, Dolan R J, Grasby P M, Warrington S J, Gunn K, Cuddigan M, Turton D J, Osman S, Frackowiak R S
MRC Cyclotron Unit, Hammersmith Hospital, London, UK.
Psychopharmacology (Berl). 1993;112(2-3):308-14. doi: 10.1007/BF02244926.
Positron emission tomography (PET) and 11C-raclopride were used to measure the occupancy of central dopamine D2 receptors by a new neuroleptic, CP-88,059-1. In a double blind dose escalation study, seven healthy male subjects received a predose of between 2 mg and 60 mg CP-88,059-1, 5 h before PET scanning. One additional subject was assigned to placebo predose. Receptor occupancy was defined as the percentage reduction in binding potential compared with that seen in the subject predosed with placebo and with that seen in seven unmedicated normal volunteers previously studied. Binding of 11C-raclopride decreased in a dose dependent manner, and 85% dopamine D2 receptor occupancy was achieved with the highest dose of CP-88,059-1. The findings confirm that brain dopamine D2 receptors are blocked by CP-88,059-1 and suggest that an effective antipsychotic dose will be between 20 mg and 40 mg. The study high-lights the potential of positron emission tomography in the preclinical evaluation of new drugs.
正电子发射断层扫描(PET)和11C-雷氯必利被用于测定一种新型抗精神病药物CP-88,059-1对中枢多巴胺D2受体的占有率。在一项双盲剂量递增研究中,7名健康男性受试者在PET扫描前5小时接受了2毫克至60毫克CP-88,059-1的预给药。另外一名受试者被分配接受安慰剂预给药。受体占有率被定义为与接受安慰剂预给药的受试者以及之前研究的7名未用药正常志愿者相比,结合潜能降低的百分比。11C-雷氯必利的结合呈剂量依赖性降低,最高剂量的CP-88,059-1可实现85%的多巴胺D2受体占有率。这些发现证实CP-88,059-1可阻断脑内多巴胺D2受体,并提示有效抗精神病剂量将在20毫克至40毫克之间。该研究突出了正电子发射断层扫描在新药临床前评估中的潜力。